BACKGROUND: Nonocclusive mesenteric ischemia (NOMI) is an emerging condition in hemodialysis (HD) patients not widely studied. MATERIALS AND METHODS: A retrospective study was conducted between 2003 and 2011. NOMI cases were recorded, and demographic, clinical, biochemical, and HD parameters were collected. This group was compared with a control group (n = 93). Risk factors, prognosis, and survival were analyzed. RESULTS: There were 57 episodes of NOMI (incidence, 2.29 episodes per 100 patients/y). Cecum was the most frequently affected segment. Nineteen patients (33%) underwent surgery. Twenty-six patients (59%) did not survive the acute episode. Cecal damage was the only protective factor associated with mortality (relative risk [RR], 0.712; P = 0.044). The incidence of NOMI was related to erythropoietin resistance index, diabetes mellitus, and longer time on HD compared with control group (RR, 6.92, P = 0.009; RR, 9.98, P = 0.005; and RR, 1.017, P < 0.001, respectively). Mortality in survival NOMI patients was higher at 4-y follow-up compared with that in the control group (log-rank, 15.5; P < 0.0001). CONCLUSIONS: NOMI is associated with erythropoietin resistance index, diabetes mellitus, and longer time on HD. Hypotension must be avoided in these high-risk patients to prevent NOMI.
BACKGROUND: Nonocclusive mesenteric ischemia (NOMI) is an emerging condition in hemodialysis (HD) patients not widely studied. MATERIALS AND METHODS: A retrospective study was conducted between 2003 and 2011. NOMI cases were recorded, and demographic, clinical, biochemical, and HD parameters were collected. This group was compared with a control group (n = 93). Risk factors, prognosis, and survival were analyzed. RESULTS: There were 57 episodes of NOMI (incidence, 2.29 episodes per 100 patients/y). Cecum was the most frequently affected segment. Nineteen patients (33%) underwent surgery. Twenty-six patients (59%) did not survive the acute episode. Cecal damage was the only protective factor associated with mortality (relative risk [RR], 0.712; P = 0.044). The incidence of NOMI was related to erythropoietin resistance index, diabetes mellitus, and longer time on HD compared with control group (RR, 6.92, P = 0.009; RR, 9.98, P = 0.005; and RR, 1.017, P < 0.001, respectively). Mortality in survival NOMI patients was higher at 4-y follow-up compared with that in the control group (log-rank, 15.5; P < 0.0001). CONCLUSIONS: NOMI is associated with erythropoietin resistance index, diabetes mellitus, and longer time on HD. Hypotension must be avoided in these high-risk patients to prevent NOMI.
Authors: Eun Young Seong; Yuanchao Zheng; Wolfgang C Winkelmayer; Maria E Montez-Rath; Tara I Chang Journal: Clin J Am Soc Nephrol Date: 2018-09-20 Impact factor: 8.237
Authors: Ashley Y Choi; Jatin Anand; Muath Bishawi; Samantha E Halpern; Fabian J Contreras; Michelle A Mendiola; Mani A Daneshmand; Jacob N Schroder; Cory Vatsaas; Suresh M Agarwal; Carmelo A Milano Journal: ASAIO J Date: 2021-08-20 Impact factor: 3.826
Authors: Samuel A Käser; Tara C Müller; Anna Guggemos; Ulrich Nitsche; Christoph Späth; Christoph A Maurer; Klaus-Peter Janssen; Jörg Kleeff; Helmut Friess; Dirk Wilhelm; Franz G Bader Journal: BMC Surg Date: 2015-03-21 Impact factor: 2.102
Authors: Klaus Stahl; Markus Busch; Sabine K Maschke; Andrea Schneider; Michael P Manns; Jan Fuge; Olaf Wiesner; Bernhard C Meyer; Marius M Hoeper; Jan B Hinrichs; Sascha David Journal: J Intensive Care Med Date: 2019-03-25 Impact factor: 3.510